Crossmark

Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy

Published Online: 2025-12-10

Authors

Soyaltin, Utku https://orcid.org/0000-0003-0229-3452
Simsir, Ilgin Y.

Akinci, Baris
License Information

Text and Data Mining valid from 2025-12-10

Version of Record valid from 2025-12-10
More Information

Article History

Received: 3 September 2025

Accepted: 29 November 2025

First Online: 10 December 2025

Declarations

:

: BA attended advisory board meetings organized by Amryt Pharmaceuticals and Regeneron Pharmaceuticals and has served as a consultant and/or received honoraria as a speaker from Third Rock Ventures, Amryt, Regeneron, AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. Other authors report no conflicts of interest.

: This study was approved by the Institutional Review Board (IRB) of the Dokuz Eylul University Medical School Hospital (IRB; 7364 GOA) in accordance with the Declaration of Helsinki. The study involves prospectively collected data so informed consent was taken all of the study participants.

Document is current